{"id":7625,"date":"2024-03-07T10:28:22","date_gmt":"2024-03-07T18:28:22","guid":{"rendered":"https:\/\/www.promisdx.com\/?p=7625"},"modified":"2024-04-29T11:03:18","modified_gmt":"2024-04-29T18:03:18","slug":"clinical-validation-of-the-proenkephalin-penk-methylation-urine-test-for-monitoring-recurrence-of-non-muscle-invasive-bladder-cancer","status":"publish","type":"post","link":"https:\/\/www.promisdx.com\/?p=7625","title":{"rendered":"Clinical Validation of the Proenkephalin (<em>PENK<\/em>) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row full_width=&#8221;stretch_row_content_no_spaces&#8221;][vc_column][vc_empty_space height=&#8221;&#8221; el_class=&#8221;header_news&#8221; css=&#8221;.vc_custom_1678221691977{background-image: url(https:\/\/www.promisdx.com\/wp-content\/uploads\/2022\/12\/newstemplateheader.png?id=6109) !important;}&#8221;][\/vc_column][\/vc_row][vc_section full_width=&#8221;stretch_row&#8221;][vc_row full_width=&#8221;stretch_row&#8221; layout=&#8221;boxed&#8221; css=&#8221;.vc_custom_1679355419891{margin-top: 1vw !important;}&#8221;][vc_column][vc_custom_heading text=&#8221;Clinical Validation of the Proenkephalin (<em>PENK<\/em>) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer&#8221; font_container=&#8221;tag:h2|text_align:left|color:%230074b7|line_height:1&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:400%20regular%3A400%3Anormal&#8221; el_class=&#8221;min-txt-body-head&#8221;][vc_column_text el_class=&#8221;body-text&#8221;]<\/p>\n<p style=\"text-align: left;\"><strong>Irvine, California, March<\/strong><strong> 7, 2024<\/strong><\/p>\n<p>In a groundbreaking study published in European Urology Open Science, researchers have validated a novel urine-based test for monitoring the recurrence of non-muscle-invasive bladder cancer (NMIBC), offering a less invasive and potentially more accurate method for patient follow-up care. The test, called the EarlyTect BC test, based on the methylation levels of the proenkephalin (PENK) gene in urine, outperforms current surveillance methods, including cytology and the NMP22 test, in detecting recurrent bladder cancer.<\/p>\n<p>The EarlyTect BC (mePENK) test marks a significant breakthrough in the surveillance of non-muscle-invasive bladder cancer (NMIBC). This novel urine-based diagnostic tool leverages the detection of methylation levels in the proenkephalin (PENK) gene to monitor the recurrence of NMIBC with a notable degree of accuracy and less invasiveness compared to traditional methods. This innovative approach not only boasts a sensitivity of 76.3% and a specificity of 85% in detecting NMIBC recurrence, significantly surpassing the performance of existing surveillance methods like cytology and the NMP22 test, but it also demonstrates significant prognostic value. Patients with positive results from the EarlyTect BC (mePENK) test experience significantly shorter recurrence-free intervals than those with negative outcomes, indicating a heightened risk of cancer recurrence.<\/p>\n<div><\/div>\n<div>The introduction of the EarlyTect BC (mePENK) test into clinical practice promises to transform NMIBC follow-up care. By providing a non-invasive, accurate method for detecting recurrence, particularly in high-risk patients, this test has the potential to streamline surveillance protocols, minimize the need for frequent cystoscopies, and significantly improve the quality of life for individuals living with NMIBC.<\/div>\n<div style=\"text-align: center;\">&#8230;<\/div>\n<div>Read the rest of the article <a href=\"https:\/\/www.eu-openscience.europeanurology.com\/article\/S2666-1683(24)00267-2\/fulltext\">here<\/a>.<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row full_width=&#8221;stretch_row_content_no_spaces&#8221;][vc_column][vc_empty_space height=&#8221;&#8221; el_class=&#8221;header_news&#8221; css=&#8221;.vc_custom_1678221691977{background-image: url(https:\/\/www.promisdx.com\/wp-content\/uploads\/2022\/12\/newstemplateheader.png?id=6109) !important;}&#8221;][\/vc_column][\/vc_row][vc_section full_width=&#8221;stretch_row&#8221;][vc_row full_width=&#8221;stretch_row&#8221; layout=&#8221;boxed&#8221; css=&#8221;.vc_custom_1679355419891{margin-top: 1vw !important;}&#8221;][vc_column][vc_custom_heading text=&#8221;Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer&#8221; font_container=&#8221;tag:h2|text_align:left|color:%230074b7|line_height:1&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:400%20regular%3A400%3Anormal&#8221; el_class=&#8221;min-txt-body-head&#8221;][vc_column_text el_class=&#8221;body-text&#8221;] Irvine, California, March 7, 2024 In a groundbreaking study published in European Urology Open Science, researchers have validated a novel urine-based test [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":7612,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[458],"tags":[],"class_list":["post-7625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer - Promis DX<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.promisdx.com\/?p=7625\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer - Promis DX\" \/>\n<meta property=\"og:description\" content=\"[vc_row full_width=&#8221;stretch_row_content_no_spaces&#8221;][vc_column][vc_empty_space height=&#8221;&#8221; el_class=&#8221;header_news&#8221; css=&#8221;.vc_custom_1678221691977{background-image: url(https:\/\/www.promisdx.com\/wp-content\/uploads\/2022\/12\/newstemplateheader.png?id=6109) !important;}&#8221;][\/vc_column][\/vc_row][vc_section full_width=&#8221;stretch_row&#8221;][vc_row full_width=&#8221;stretch_row&#8221; layout=&#8221;boxed&#8221; css=&#8221;.vc_custom_1679355419891{margin-top: 1vw !important;}&#8221;][vc_column][vc_custom_heading text=&#8221;Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer&#8221; font_container=&#8221;tag:h2|text_align:left|color:%230074b7|line_height:1&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:400%20regular%3A400%3Anormal&#8221; el_class=&#8221;min-txt-body-head&#8221;][vc_column_text el_class=&#8221;body-text&#8221;] Irvine, California, March 7, 2024 In a groundbreaking study published in European Urology Open Science, researchers have validated a novel urine-based test [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.promisdx.com\/?p=7625\" \/>\n<meta property=\"og:site_name\" content=\"Promis DX\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/promisdx\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-07T18:28:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-29T18:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"225\" \/>\n\t<meta property=\"og:image:height\" content=\"225\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Promis DX\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Promis DX\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.promisdx.com\/?p=7625#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7625\"},\"author\":{\"name\":\"Promis DX\",\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/person\/c085d00d0271456e681a0f53a6ddc637\"},\"headline\":\"Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer\",\"datePublished\":\"2024-03-07T18:28:22+00:00\",\"dateModified\":\"2024-04-29T18:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7625\"},\"wordCount\":396,\"publisher\":{\"@id\":\"https:\/\/www.promisdx.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7625#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg?fit=225%2C225&ssl=1\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.promisdx.com\/?p=7625\",\"url\":\"https:\/\/www.promisdx.com\/?p=7625\",\"name\":\"Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer - Promis DX\",\"isPartOf\":{\"@id\":\"https:\/\/www.promisdx.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7625#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7625#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg?fit=225%2C225&ssl=1\",\"datePublished\":\"2024-03-07T18:28:22+00:00\",\"dateModified\":\"2024-04-29T18:03:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.promisdx.com\/?p=7625#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.promisdx.com\/?p=7625\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.promisdx.com\/?p=7625#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg?fit=225%2C225&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg?fit=225%2C225&ssl=1\",\"width\":225,\"height\":225},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.promisdx.com\/?p=7625#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.promisdx.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.promisdx.com\/#website\",\"url\":\"https:\/\/www.promisdx.com\/\",\"name\":\"PromisDx\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.promisdx.com\/#organization\"},\"alternateName\":\"Promis Dx\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.promisdx.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.promisdx.com\/#organization\",\"name\":\"Promis DX\",\"url\":\"https:\/\/www.promisdx.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.promisdx.com\/wp-content\/uploads\/2021\/02\/PromisDx_Logo_2_RGB.png\",\"contentUrl\":\"https:\/\/www.promisdx.com\/wp-content\/uploads\/2021\/02\/PromisDx_Logo_2_RGB.png\",\"width\":2223,\"height\":901,\"caption\":\"Promis DX\"},\"image\":{\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/promisdx\",\"https:\/\/www.linkedin.com\/company\/promisdx\",\"https:\/\/www.instagram.com\/promisdx\/?igshid=YmMyMTA2M2Y\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/person\/c085d00d0271456e681a0f53a6ddc637\",\"name\":\"Promis DX\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.promisdx.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/879c3dc78687f595be7e01d63d40db85133d212512634d874b308c32f288b6e4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/879c3dc78687f595be7e01d63d40db85133d212512634d874b308c32f288b6e4?s=96&d=mm&r=g\",\"caption\":\"Promis DX\"},\"url\":\"https:\/\/www.promisdx.com\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer - Promis DX","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.promisdx.com\/?p=7625","og_locale":"en_US","og_type":"article","og_title":"Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer - Promis DX","og_description":"[vc_row full_width=&#8221;stretch_row_content_no_spaces&#8221;][vc_column][vc_empty_space height=&#8221;&#8221; el_class=&#8221;header_news&#8221; css=&#8221;.vc_custom_1678221691977{background-image: url(https:\/\/www.promisdx.com\/wp-content\/uploads\/2022\/12\/newstemplateheader.png?id=6109) !important;}&#8221;][\/vc_column][\/vc_row][vc_section full_width=&#8221;stretch_row&#8221;][vc_row full_width=&#8221;stretch_row&#8221; layout=&#8221;boxed&#8221; css=&#8221;.vc_custom_1679355419891{margin-top: 1vw !important;}&#8221;][vc_column][vc_custom_heading text=&#8221;Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer&#8221; font_container=&#8221;tag:h2|text_align:left|color:%230074b7|line_height:1&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:400%20regular%3A400%3Anormal&#8221; el_class=&#8221;min-txt-body-head&#8221;][vc_column_text el_class=&#8221;body-text&#8221;] Irvine, California, March 7, 2024 In a groundbreaking study published in European Urology Open Science, researchers have validated a novel urine-based test [&hellip;]","og_url":"https:\/\/www.promisdx.com\/?p=7625","og_site_name":"Promis DX","article_publisher":"https:\/\/www.facebook.com\/promisdx","article_published_time":"2024-03-07T18:28:22+00:00","article_modified_time":"2024-04-29T18:03:18+00:00","og_image":[{"width":225,"height":225,"url":"https:\/\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg","type":"image\/jpeg"}],"author":"Promis DX","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Promis DX","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.promisdx.com\/?p=7625#article","isPartOf":{"@id":"https:\/\/www.promisdx.com\/?p=7625"},"author":{"name":"Promis DX","@id":"https:\/\/www.promisdx.com\/#\/schema\/person\/c085d00d0271456e681a0f53a6ddc637"},"headline":"Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer","datePublished":"2024-03-07T18:28:22+00:00","dateModified":"2024-04-29T18:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.promisdx.com\/?p=7625"},"wordCount":396,"publisher":{"@id":"https:\/\/www.promisdx.com\/#organization"},"image":{"@id":"https:\/\/www.promisdx.com\/?p=7625#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg?fit=225%2C225&ssl=1","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.promisdx.com\/?p=7625","url":"https:\/\/www.promisdx.com\/?p=7625","name":"Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer - Promis DX","isPartOf":{"@id":"https:\/\/www.promisdx.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.promisdx.com\/?p=7625#primaryimage"},"image":{"@id":"https:\/\/www.promisdx.com\/?p=7625#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg?fit=225%2C225&ssl=1","datePublished":"2024-03-07T18:28:22+00:00","dateModified":"2024-04-29T18:03:18+00:00","breadcrumb":{"@id":"https:\/\/www.promisdx.com\/?p=7625#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.promisdx.com\/?p=7625"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.promisdx.com\/?p=7625#primaryimage","url":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg?fit=225%2C225&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg?fit=225%2C225&ssl=1","width":225,"height":225},{"@type":"BreadcrumbList","@id":"https:\/\/www.promisdx.com\/?p=7625#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.promisdx.com\/"},{"@type":"ListItem","position":2,"name":"Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non\u2013muscle-invasive Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.promisdx.com\/#website","url":"https:\/\/www.promisdx.com\/","name":"PromisDx","description":"","publisher":{"@id":"https:\/\/www.promisdx.com\/#organization"},"alternateName":"Promis Dx","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.promisdx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.promisdx.com\/#organization","name":"Promis DX","url":"https:\/\/www.promisdx.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.promisdx.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.promisdx.com\/wp-content\/uploads\/2021\/02\/PromisDx_Logo_2_RGB.png","contentUrl":"https:\/\/www.promisdx.com\/wp-content\/uploads\/2021\/02\/PromisDx_Logo_2_RGB.png","width":2223,"height":901,"caption":"Promis DX"},"image":{"@id":"https:\/\/www.promisdx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/promisdx","https:\/\/www.linkedin.com\/company\/promisdx","https:\/\/www.instagram.com\/promisdx\/?igshid=YmMyMTA2M2Y"]},{"@type":"Person","@id":"https:\/\/www.promisdx.com\/#\/schema\/person\/c085d00d0271456e681a0f53a6ddc637","name":"Promis DX","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.promisdx.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/879c3dc78687f595be7e01d63d40db85133d212512634d874b308c32f288b6e4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/879c3dc78687f595be7e01d63d40db85133d212512634d874b308c32f288b6e4?s=96&d=mm&r=g","caption":"Promis DX"},"url":"https:\/\/www.promisdx.com\/?author=4"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.promisdx.com\/wp-content\/uploads\/2024\/03\/download.jpg?fit=225%2C225&ssl=1","_links":{"self":[{"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/posts\/7625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7625"}],"version-history":[{"count":0,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/posts\/7625\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=\/wp\/v2\/media\/7612"}],"wp:attachment":[{"href":"https:\/\/www.promisdx.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.promisdx.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}